Here are relevant reports on : cardiovascular-diseases-market
-
Gastrointestinal Products Market | Gastroenterology Products Market by Devices (Endoscopy, Ablation system, Motility testing, Biopsy devices, Stenting devices, pH monitoring), Diseases (GERD), (IBD), Gastrointestinal cancer), End-User (Hospitals, ASC) - Global Forecast to 2029
The global gastrointestinal products market, valued at US$13.8 million in 2023, stood at US$14.7 million in 2024 and is projected to advance at a resilient CAGR of 6.1% from 2024 to 2029, culminating in a forecasted valuation of US$19.7 million by the end of the period. Market growth can be attributed to the growing prevalence of gastrointestinal diseases such as Crohn's disease, ulcerative colitis, irritable bowel syndrome (IBS), and colorectal cancer, which drives the demand for diagnostic and therapeutic products.
- Published: August 2024
- Price: $ 4950
- TOC Available:
-
PEGylated Proteins Market by Consumables (PEGylation Kits, Reagents), Services, Protein Type (mAbs, Interferons), Application (Cancer Treatment, Chronic Kidney Diseases), End-User (Pharmaceutical & Biotechnology Companies)- Global Forecast to 2021
The global PEGylated proteins market size is projected to grow at a CAGR of 10.5%. The major drivers for the market include increase in R&D spending of pharmaceutical & biotechnology companies, growth in biologics sector, high prevalence of lifestyle disease, increasing focus on strategies to improve protein stability and circulating half-life. The rising opportunities in emerging markets and top-selling biologics drugs going off-patent in the near future will provide new growth opportunities for this market.
- Published: November 2016
- Price: $ 4950
- TOC Available:
-
Asia Pacific Human Microbiome Market by Drug & Supplement (Drugs, Probiotics, Prebiotics), Disease (Infectious, Gastrointestinal, Endocrine & Metabolic Diseases), Type (BCT/FMT, LBP), End User (Hospitals, Clinics, Long-term Care) - Forecast to 2031
The Asia Pacific Human Microbiome Market, valued at US$0.19 billion in 2024, stood at US$0.26 billion in 2025 and is projected to advance at a resilient CAGR of 31.0% from 2025 to 2031, culminating in a forecasted valuation of US$1.31 billion by the end of the period. Market growth is driven by an increasing focus on preventive and personalized health, rising adoption of microbiome-based diagnostics and therapeutic solutions, and rapid advances in next-generation sequencing, AI-enabled microbiome analytics, and regional bioinformatics capabilities.
- Published: March 2026
- Price: $ 4950
- TOC Available:
-
Europe In Vitro Diagnostics Market by Product & Service (Kits, Instruments), Technology (Immunoassay, Hematology, Glucose Monitoring), Specimen (Blood), Site of Testing, Application (Endocrinology, Cardiology, Infectious Diseases) - Forecast to 2031
The Europe in vitro diagnostics (IVD) market, valued at USD 31.43 billion in 2025, stood at USD 33.83 billion in 2026 and is projected to advance at a resilient CAGR of 7.9% from 2026 to 2031, culminating in a forecasted valuation of USD 49.49 billion by the end of the period. Market growth is driven by rising diagnostic test volumes across national healthcare systems, broader adoption of population-based screening programs, and increasing emphasis on standardized disease monitoring.
- Published: January 2026
- Price: $ 4950
- TOC Available:
-
Oligonucleotide Therapeutics Market by Molecule (Nusinersen, Vutrisiran, Inclisiran, Eteplisiran), Type (ASO, siRNA, Others), Disease Type (Neurology, Rare Diseases, Others), RoA (SC, Intrathecal, IV, Others), and Region - Global Forecast to 2030
The global oligonucleotide therapeutics market, valued at US$5.92 billion in 2024, stood at US$7.19 billion in 2025 and is projected to advance at a resilient CAGR of 19.7% from 2025 to 2030, culminating in a forecasted valuation of US$17.70 billion by the end of the period. The market is growing as more RNA-targeting therapies gain broader clinical acceptance. This increase is mainly driven by siRNAs and antisense candidates, supported by advances in delivery technologies like GalNAc conjugates and lipid nanoparticles.
- Published: January 2026
- Price: $ 4950
- TOC Available:
-
Sexually Transmitted Diseases Diagnostics Market by Disease Type (CT/NG, Gonorrhea, Syphilis, Genital Herpes, Hepatitis B, HIV/AIDS, HPV), End User (Laboratory, PoC) and Geography - Global Forecast to 2027
The STDs diagnostics market size is projected to reach $99,431.6 million by 2027 from $91,441.5 million in 2022, at a CAGR of 5.6% during the forecast period. Sexually transmitted diseases diagnostics market is driven by factors such as global prevalence of HIV, CT/NG, and other STDs and the growing awareness for early disease diagnosis, shift in focus from centralized laboratories to decentralized POC testing and rising technological advancements. On the other hand, an unfavorable reimbursement scenario is expected to limit market growth to a certain extent in the coming years.
- Published: March 2026
- Price: $ 4950
- TOC Available:
-
Urology Surgical Instruments Market by Product (Endoscopes, Endovision Systems, Peripheral Instruments, Consumables and Accessories), Application (Chronic Kidney Diseases, Benign Prostatic Hyperplasia, Oncology) - Global Forecast to 2021
The global urology surgical instruments market size is projected to grow at a CAGR of 8.2%. The growth of this market can be contributed to rising prevalence of kidney diseases and urinary tract infections; rising number of hospitals and growing hospital investments in surgical infrastructure; availability of investments, funds, and grants from government bodies; and rising geriatric population.
- Published: September 2016
- Price: $ 4950
- TOC Available:
-
Esoteric Testing Market by Type (Endocrinology, Oncology, Neurology, Genetic Tests, Autoimmune, Infectious Diseases), Technology (ELISA, CLIA, Flow Cytometry, NGS, RT-PCR, Chromatography, Spectrometry), Specimen (Blood, Urine) - Global Forecast to 2029
The global esoteric testing market, valued at US$29.9 billion in 2023, stood at US$32.2 billion in 2024 and is projected to advance at a resilient CAGR of 8.5% from 2024 to 2029, culminating in a forecasted valuation of US$48.3 billion by the end of the period. Growth in the market is primarily driven by the growing geriatric population, advancements in esoteric tests for personalized medicine, increasing research funding for precision medicine, and increase in drug and alcohol abuse and stringent laws mandating drug and alcohol testing.
- Published: June 2024
- Price: $ 4950
- TOC Available:
-
Asia Pacific In Vitro Diagnostics Market by Product & Service (Kits, Instruments), Technology (Immunoassay, Hematology, Glucose Monitoring), Specimen (Blood), Site of Testing, Application (Endocrinology, Cardiology, Infectious Diseases) - Forecast to 2031
The Asia Pacific in vitro diagnostics market is valued at an estimated USD 29.27 billion in 2026 and is projected to reach USD 45.11 billion by 2031 at a CAGR of 9.0% during the forecast period. The Key Players F. Hoffmann-La Roche Ltd (Switzerland), Abbott (US), Danaher (US), Sysmex Corporation (Japan), Shenzhen Mindray Bio-Medical Electronics Co., (China)., Siemens Healthineers AG (Germany), bioMérieux (France), Illumina, Inc. (US), Becton, Dickinson and Company (US), and QuidelOrtho Corporation (US).
- Published: March 2026
- Price: $ 4950
- TOC Available:
-
Vitamin D Therapy Market by Route of administration (Oral, Parenteral), Age Group (Children, Adult, Senior Adult), Purchase Pattern (OTC, Prescription), Application (Osteoporosis, Rickets, Autoimmune Disorder, Skin Diseases) - Global Forecast to 2024
The vitamin D therapy market is projected to reach USD 3.3 billion by 2024 from USD 1.9 billion in 2019, at a CAGR of 11.6% during the forecast period. Growth in this market is largely driven by the growing awareness about vitamin D deficiency and the presence of a large target patient population. On the other hand, the fortification of foods is likely to challenge the growth of this market. Some of the major players in this market include Abbott (US), Sanofi (France), GlaxoSmithKline plc (UK), Pfizer Inc. (US), Merck & Co., Inc. (US), Torrent Pharmaceuticals Ltd. (India), Novartis International AG (Switzerland), Alkem Laboratories (India), Sun Pharmaceutical Industries Ltd. (India), and Cadila Healthcare Ltd. (India).
- Published: April 2019
- Price: $ 4950
- TOC Available:
Records 11 to 20 of 50
